GlassScriptPhysician profile
John G Fan
NPI 1225099203
$15,855.08
in general payments reported to CMS, 2019-2025
24 companies · $798 in 2025
The $798 reported for 2025 was more than what 85% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,006 · 2020: $1,567 · 2021: $624 · 2022: $3,780 · 2023: $1,099 · 2024: $1,982 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,092 · Travel and Lodging: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,091.52 |
| Travel and Lodging | $787.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,834.56 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Medtronic USA, INC. | $2,741.15 | 2019-2020 | |
| Nevro Corp. | $2,339.59 | 2019-2024 | Senza |
| Stryker Corporation | $1,000.95 | 2019-2020 | |
| Titan Pharmaceuticals, INC. | $941.54 | 2019 | |
| Amgen INC. | $376.31 | 2019-2024 | Evenity, Prolia |
| Collegium Pharmaceutical, INC. | $255.19 | 2019-2021 | |
| Spinal Simplicity, LLC | $226.73 | 2023 | Ha Minuteman G3-R |
| Averitas Pharma INC. | $217.67 | 2023-2025 | Qutenza |
| Si-Bone, INC. | $179.48 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $117.10 | 2019-2021 | |
| Pfizer INC. | $102.24 | 2019-2024 | |
| Allergan, INC. | $98.68 | 2019-2021 | |
| Abbvie INC. | $79.82 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.44 | 2023 | Relistor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $46.44 | 2022-2023 | Wegovy |
| Daiichi Sankyo INC. | $41.33 | 2019 | |
| Grt US Holding, INC. | $37.99 | 2022 | |
| Tersera Therapeutics LLC | $36.75 | 2019-2020 | |
| Radius Health, INC. | $31.82 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $28.42 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $24.89 | 2021 | |
| Horizon Therapeutics Plc | $19.68 | 2022 | |
| Merit Medical Systems INC | $14.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.